| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Liu G, Lipari P, Mollin A, Jung S, Teplova I, Li W, Ying L, More V, Lennox W, Yeh S, McGann E, Moon YC, Rice C, Huarte E, Gruszka B, et al. Comparison of pharmaceutical properties and biological activity of prednisolone, deflazacort, and vamorolone in DMD disease models. Human Molecular Genetics. PMID 37819629 DOI: 10.1093/hmg/ddad173 |
0.01 |
|
| 2022 |
Baiazitov RY, Qi H, Arasu T, Lennox W, Cao L, Weetall M, Furia B, Zhuo J, Choi S, Kim MJ, Sheedy J, Davis T, Moon YC. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor. European Journal of Medicinal Chemistry. 244: 114826. PMID 36242990 DOI: 10.1016/j.ejmech.2022.114826 |
0.01 |
|
| 2021 |
Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, Kuribayashi W, Oshima M, Nakajima-Takagi Y, Yamashita M, Mimura N, Becker HJ, Izawa K, Yamazaki S, Iwano S, ... ... Lennox W, et al. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes. Blood Advances. 5: 438-450. PMID 33496740 DOI: 10.1182/bloodadvances.2020001461 |
0.01 |
|
| 2021 |
Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, ... ... Lennox W, et al. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Scientific Reports. 11: 2074. PMID 33483574 DOI: 10.1038/s41598-021-81577-x |
0.01 |
|
| 2020 |
Zhong C, Kayamori K, Koide S, Shinoda D, Oshima M, Nakajima-Takagi Y, Nagai Y, Mimura N, Sakaida E, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Yamaguchi K, ... ... Lennox W, et al. Efficacy of the Novel Tubulin Polymerization Inhibitor PTC-028 for Myelodysplastic Syndrome. Cancer Science. PMID 33037737 DOI: 10.1111/cas.14684 |
0.01 |
|
| 2018 |
Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, Du J, Sheedy J, Hedrick J, Risher N, Yeh S, ... ... Lennox W, et al. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics. PMID 30352802 DOI: 10.1158/1535-7163.Mct-18-0863 |
0.01 |
|
| 2016 |
Cao L, Weetall M, Bombard J, Qi H, Arasu T, Lennox W, Hedrick J, Sheedy J, Risher N, Brooks PC, Trifillis P, Trotta C, Moon YC, Babiak J, Almstead NG, et al. Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. Plos One. 11: e0168366. PMID 27992500 DOI: 10.1371/Journal.Pone.0168366 |
0.01 |
|
| 2015 |
Chen G, Ren H, Zhang N, Lennox W, Turpoff A, Paget S, Li C, Almstead N, Njoroge FG, Gu Z, Graci J, Jung SP, Colacino J, Lahser F, Zhao X, et al. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B. Bioorganic & Medicinal Chemistry Letters. 25: 781-6. PMID 25613678 DOI: 10.1016/J.Bmcl.2014.12.093 |
0.01 |
|
| 2014 |
Zhang N, Zhang X, Zhu J, Turpoff A, Chen G, Morrill C, Huang S, Lennox W, Kakarla R, Liu R, Li C, Ren H, Almstead N, Venkatraman S, Njoroge FG, et al. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. Journal of Medicinal Chemistry. 57: 2121-35. PMID 24266880 DOI: 10.1021/Jm401621G |
0.01 |
|
| 2013 |
Zhang X, Zhang N, Chen G, Turpoff A, Ren H, Takasugi J, Morrill C, Zhu J, Li C, Lennox W, Paget S, Liu Y, Almstead N, Njoroge FG, Gu Z, et al. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B. Bioorganic & Medicinal Chemistry Letters. 23: 3947-53. PMID 23683597 DOI: 10.1016/J.Bmcl.2013.04.049 |
0.01 |
|
| 2007 |
Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF, Galante R, Huang P, Dawson LA, et al. Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. Journal of Medicinal Chemistry. 50: 5535-8. PMID 17948978 DOI: 10.1021/jm070521y |
0.01 |
|
| 2005 |
Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL, Zhang G, Tawa GJ, Schechter LE. Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15: 4780-5. PMID 16125933 DOI: 10.1016/j.bmcl.2005.07.028 |
0.01 |
|
| 2005 |
Cole DC, Lennox WJ, Lombardi S, Ellingboe JW, Bernotas RC, Tawa GJ, Mazandarani H, Smith DL, Zhang G, Coupet J, Schechter LE. Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. Journal of Medicinal Chemistry. 48: 353-6. PMID 15658848 DOI: 10.1021/jm049243i |
0.01 |
|
| 2005 |
Cole DC, Ellingboe JW, Lennox WJ, Mazandarani H, Smith DL, Stock JR, Zhang G, Zhou P, Schechter LE. N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 15: 379-83. PMID 15603958 DOI: 10.1016/j.bmcl.2004.10.064 |
0.01 |
|
| 1941 |
Lennox WG. Bernard of Gordon on Epilepsy. Annals of Medical History. 3: 372-383. PMID 33943318 |
0.01 |
|
| 1940 |
Lennox WG. Antonius Guainerius on Epilepsy. Annals of Medical History. 2: 482-499. PMID 33943834 |
0.01 |
|
| 1939 |
Lennox WG. John of Gaddesden on Epilepsy. Annals of Medical History. 1: 283-307. PMID 33943467 |
0.01 |
|
| Hide low-probability matches. |